Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures

Dec 03, 2020•over 4 years ago

Amount Raised

$12 Million

Round Type

seed

Sunnyvale

Description

Rubedo Life Sciences, a biopharmaceutical company committed to developing first-in-class therapies targeting senescent cells which drive age-related diseases, today announced the closing of a $12M Seed financing round. The round was led by Khosla Ventures, with participation from Longevity Fund, Refactor Capital, Shanda and additional investors.

Company Information

Company

Rubedo Life Sciences

Location

Sunnyvale, California, United States

About

Rubedo Life Sciences is a biopharmaceutical company developing a broad portfolio of innovative therapies engineered to target cells which drive chronic age-related diseases. Our proprietary ALEMBIC™ drug discovery platform has engineered novel first-in-class small molecules designed to selectively target senescent cells, which play a key role in the progression of pulmonary, oncological, neurodegenerative, fibrotic and other chronic disorders. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, technology, and life sciences, with expertise in drug development and commercialization from both large pharma and leading biotech companies. The company is based in Sunnyvale, CA. For additional information, please visit www.rubedolife.com.

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Rubedo Life Sciences Closes $12M Seed Financing Led by Khosla Ventures

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information